Aclarion, Inc. (LSX:A412BH) Financings

Aclarion, Inc.

Financings

RaiseDate
Common stock
Closed: US$10.4M raised · US$5.18 a share · Dawson James Securities, Inc.
Dealers: Dawson James Securities, Inc. (lead)
Jan 13, 2026
Registered direct offering of common stock
Closed: US$2.5M raised
Oct 14, 2025
Registered direct offering of common stock
Announced: about US$4.7M · US$9.25 a share · Dawson James Securities, Inc.
Dealers: Dawson James Securities, Inc. (lead)
Use of proceeds: Market development and clinical evidence, product development and quality, general and administration support, and general corporate purposes
Jan 30, 2025
Public offering of common stock and pre-funded warrants with series A and series B common warrants
Closed: US$14.4M raised · US$0.1 a share · Warrants at US$0.2 · Dawson James Securities, Inc.
Dealers: Dawson James Securities, Inc. (lead)
Use of proceeds: Redeem all outstanding Series B Preferred Stock; build out product platforms, expand sales and marketing, G&A and general corporate purposes
Jan 17, 2025

Read by 6ix AI from the company's releases